Dasatinib Accordpharma

Country: European Union

Language: Italian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

dasatinib

Available from:

Accord Healthcare S.L.U.

ATC code:

L01EA02

INN (International Name):

dasatinib (anhydrous)

Therapeutic group:

Agenti antineoplastici

Therapeutic area:

Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Therapeutic indications:

Dasatinib Accordpharma is indicated for the treatment of adult patients with: newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase.  chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib.  Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy. Dasatinib Accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib.  newly diagnosed Ph+ ALL in combination with chemotherapy.

Product summary:

Revision: 1

Authorization status:

Ritirato

Authorization date:

2022-03-24

Patient Information leaflet

                                63
B. FOGLIO ILLUSTRATIVO
Medicinale non più autorizzato
64
FOGLIO ILLUSTRATIVO: INFORMAZIONI PER L'UTILIZZATORE
DASATINIB ACCORDPHARMA 20 MG COMPRESSE RIVESTITE CON FILM
DASATINIB ACCORDPHARMA 50 MG COMPRESSE RIVESTITE CON FILM
DASATINIB ACCORDPHARMA 70 MG COMPRESSE RIVESTITE CON FILM
DASATINIB ACCORDPHARMA 80 MG COMPRESSE RIVESTITE CON FILM
DASATINIB ACCORDPHARMA 100 MG COMPRESSE RIVESTITE CON FILM
DASATINIB ACCORDPHARMA 140 MG COMPRESSE RIVESTITE CON FILM
dasatinib
LEGGA ATTENTAMENTE QUESTO FOGLIO PRIMA DI PRENDERE QUESTO MEDICINALE
PERCHÉ CONTIENE
IMPORTANTI INFORMAZIONI PER LEI.
▪
Conservi questo foglio. Potrebbe aver bisogno di leggerlo di nuovo.
▪
Se ha qualsiasi dubbio, si rivolga al medico o al farmacista.
▪
Questo medicinale è stato prescritto soltanto per lei. Non lo dia ad
altre persone, anche se i
sintomi della malattia sono uguali ai suoi, perchè potrebbe essere
pericoloso.
▪
Se si manifesta un qualsiasi effetto indesiderato, compresi quelli non
elencati in questo foglio, si
rivolga al medico o al farmacista. Vedere paragrafo 4.
CONTENUTO DI QUESTO FOGLIO:
1.
Cos'è Dasatinib Accordpharma e a cosa serve
2.
Cosa deve sapere prima di prendere Dasatinib Accordpharma
3.
Come prendere Dasatinib Accordpharma
4.
Possibili effetti indesiderati
5.
Come conservare Dasatinib Accordpharma
6.
Contenuto della confezione e altre informazioni
1.
COS'È DASATINIB ACCORDPHARMA E A COSA SERVE
Dasatinib Accordpharma contiene la sostanza attiva dasatinib. Questo
medicinale viene utilizzato per
il trattamento della leucemia mieloide cronica (LMC) negli adulti,
negli adolescenti e nei bambini di
almeno 1 anno di età. La leucemia è un tumore dei globuli bianchi. I
globuli bianchi normalmente
aiutano l'organismo a combattere le infezioni. Negli individui affetti
da LMC, i globuli bianchi
chiamati granulociti iniziano a crescere senza controllo. Dasatinib
Accordpharma inibisce la crescita di
queste cellule leucemiche.
Dasatinib Accordpharma viene anche utilizzato per il trattamento della
leucemia linfoblastica 
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ALLEGATO I
RIASSUNTO DELLE CARATTERISTICHE DEL PRODOTTO
Medicinale non più autorizzato
2
1.
DENOMINAZIONE DEL MEDICINALE
Dasatinib Accordpharma 20 mg compresse rivestite con film
Dasatinib Accordpharma 50 mg compresse rivestite con film
Dasatinib Accordpharma 70 mg compresse rivestite con film
Dasatinib Accordpharma 80 mg compresse rivestite con film
Dasatinib Accordpharma 100 mg compresse rivestite con film
Dasatinib Accordpharma 140 mg compresse rivestite con film
2.
COMPOSIZIONE QUALITATIVA E QUANTITATIVA
Dasatinib Accordpharma 20 mg compresse rivestite con film
Ogni compressa rivestita con film contiene 20 mg di dasatinib.
_Eccipiente con effetti noti _
Ogni compressa rivestita con film contiene 27 mg di lattosio (come
monoidrato).
Dasatinib Accordpharma 50 mg compresse rivestite con film
Ogni compressa rivestita con film contiene 50 mg di dasatinib.
_Eccipiente con effetti noti _
Ogni compressa rivestita con film contiene 67,5 mg di lattosio (come
monoidrato).
Dasatinib Accordpharma 70 mg compresse rivestite con film
Ogni compressa rivestita con film contiene 70 mg di dasatinib.
_Eccipiente con effetti noti _
Ogni compressa rivestita con film contiene 94,5 mg di lattosio (come
monoidrato).
Dasatinib Accordpharma 80 mg compresse rivestite con film
Ogni compressa rivestita con film contiene 80 mg di dasatinib.
_Eccipiente con effetti noti _
Ogni compressa rivestita con film contiene 108 mg di lattosio (come
monoidrato).
Dasatinib Accordpharma 100 mg compresse rivestite con film
Ogni compressa rivestita con film contiene 100 mg di dasatinib.
_Eccipiente con effetti noti _
Ogni compressa rivestita con film contiene 135 mg di lattosio (come
monoidrato).
Dasatinib Accordpharma 140 mg compresse rivestite con film
Ogni compressa rivestita con film contiene 140 mg di dasatinib.
_Eccipiente con effetti noti _
Ogni compressa rivestita con film contiene 189 mg di lattosio (come
monoidrato).
Per l'elenco completo degli eccipienti, vedere paragrafo 6.1.
3.
FORMA FARMACEUTICA
Compressa rivestita con film (compressa).
Da
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 30-03-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 30-03-2023
Public Assessment Report Public Assessment Report Bulgarian 30-03-2023
Patient Information leaflet Patient Information leaflet Spanish 30-03-2023
Public Assessment Report Public Assessment Report Spanish 30-03-2023
Patient Information leaflet Patient Information leaflet Czech 30-03-2023
Public Assessment Report Public Assessment Report Czech 30-03-2023
Patient Information leaflet Patient Information leaflet Danish 30-03-2023
Public Assessment Report Public Assessment Report Danish 30-03-2023
Patient Information leaflet Patient Information leaflet German 30-03-2023
Public Assessment Report Public Assessment Report German 30-03-2023
Patient Information leaflet Patient Information leaflet Estonian 30-03-2023
Public Assessment Report Public Assessment Report Estonian 30-03-2023
Patient Information leaflet Patient Information leaflet Greek 30-03-2023
Public Assessment Report Public Assessment Report Greek 30-03-2023
Patient Information leaflet Patient Information leaflet English 30-03-2023
Public Assessment Report Public Assessment Report English 30-03-2023
Patient Information leaflet Patient Information leaflet French 30-03-2023
Public Assessment Report Public Assessment Report French 30-03-2023
Patient Information leaflet Patient Information leaflet Latvian 30-03-2023
Public Assessment Report Public Assessment Report Latvian 30-03-2023
Patient Information leaflet Patient Information leaflet Lithuanian 30-03-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 30-03-2023
Public Assessment Report Public Assessment Report Lithuanian 30-03-2023
Patient Information leaflet Patient Information leaflet Hungarian 30-03-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 30-03-2023
Public Assessment Report Public Assessment Report Hungarian 30-03-2023
Patient Information leaflet Patient Information leaflet Maltese 30-03-2023
Public Assessment Report Public Assessment Report Maltese 30-03-2023
Patient Information leaflet Patient Information leaflet Dutch 30-03-2023
Public Assessment Report Public Assessment Report Dutch 30-03-2023
Patient Information leaflet Patient Information leaflet Polish 30-03-2023
Public Assessment Report Public Assessment Report Polish 30-03-2023
Patient Information leaflet Patient Information leaflet Portuguese 30-03-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 30-03-2023
Public Assessment Report Public Assessment Report Portuguese 30-03-2023
Patient Information leaflet Patient Information leaflet Romanian 30-03-2023
Public Assessment Report Public Assessment Report Romanian 30-03-2023
Patient Information leaflet Patient Information leaflet Slovak 30-03-2023
Public Assessment Report Public Assessment Report Slovak 30-03-2023
Patient Information leaflet Patient Information leaflet Slovenian 30-03-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 30-03-2023
Public Assessment Report Public Assessment Report Slovenian 30-03-2023
Patient Information leaflet Patient Information leaflet Finnish 30-03-2023
Public Assessment Report Public Assessment Report Finnish 30-03-2023
Patient Information leaflet Patient Information leaflet Swedish 30-03-2023
Public Assessment Report Public Assessment Report Swedish 30-03-2023
Patient Information leaflet Patient Information leaflet Norwegian 30-03-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 30-03-2023
Patient Information leaflet Patient Information leaflet Icelandic 30-03-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 30-03-2023
Patient Information leaflet Patient Information leaflet Croatian 30-03-2023
Public Assessment Report Public Assessment Report Croatian 30-03-2023

Search alerts related to this product